MEK-ing the most of it: strategies to co-target G αq and MAPK in uveal melanoma.

MEK-ing the most of it: strategies to co-target Gαq and MAPK in uveal melanoma. Clin Cancer Res. 2020 Dec 22;: Authors: Neelature Sriramareddy S, Smalley KSM Abstract Most uveal melanomas harbor mutations in Gαq and show constitutive MAPK activation. Although MEK inhibition has some efficacy against uveal melanoma, clinical responses are typically poor. The Gαq inhibitor-MEK inhibitor combination showed prolonged suppression of MAPK signaling in preclinical uveal melanoma models and led to improved therapeutic responses. PMID: 33355300 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/33355300?dopt=Abstract

Source: Clinical Cancer Research - December 22, 2020 Category: Cancer & Oncology Authors: Neelature Sriramareddy S, Smalley KSM Tags: Clin Cancer Res Source Type: research